Clinical trials: Hemostatic Disorders
Relapsed Multiple Myeloma, Relapsed-Refractory Multiple Myeloma
Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma
This was a randomized, controlled, open-label, Phase 3 multicenter study which enrolled patients with Relapsed-Refractory Multiple Myeloma (RRMM) who were either double refractory to an Immunomodulatory Drug (IMiD) and a…
- Trial name
- LIGHTHOUSE (NCT04649060)
- Testing
- Melflufen, Dexamethasone, Daratumumab
- Where
- 26 sites in Bulgaria, Czechia and 9 more
- Volunteers
- 54 people
- Sponsor
- Oncopeptides AB
Tumors, Lymphoma
Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED)
Phase 1 trial to determine the safety, tolerability and maximum tolerated dose (MTD) of AP23573 in patients with refractory or recurrent malignancies, including myeloma and lymphoma.
- Conditions
- Tumors, Lymphoma, Multiple Myeloma
- Trial name
- NCT00060645
- Testing
- ridaforolimus
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Merck Sharp & Dohme LLC
Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition
Beta Alethine in Treating Patients With Myeloma
RATIONALE: Biological therapies such as beta alethine use different ways to stimulate the immune system and stop cancer cells from growing.
- Trial name
- NCT00006466
- Testing
- beta alethine
- Where
- 3 sites in United States
- Sponsor
- LifeTime Pharmaceuticals
Bleeding Peptic Ulcer
High Dose Esomeprazole Na for Prevention of Rebleeding After Successful Endoscopic Therapy of a Bleeding Peptic Ulcer
To describe the rate of clinically significant rebleeding during 72 hours continuous i.v. infusion of high dose esomeprazole Na in patients in China with primary successful endoscopic haemostatic therapy of a bleeding peptic…
- Trial name
- NCT01757275
- Testing
- Esomeprazole Na, Cimetidine, Esomeprazole Mg
- Where
- 12 sites in China
- Volunteers
- 239 people
- Sponsor
- AstraZeneca
Multiple Myeloma
Observational Study of the Effects Intravenous Bortezomib Has on Osteoblast (Cell That is Responsible for Bone Formation) Activity in Multiple Myeloma Patients.
The purpose of this study is to measure the markers related to bone metabolism before and after the use of bortezomib injection in patients with multiple myeloma and to evaluate the effect bortezomib injection has on bone disease.
- Trial name
- NCT01026701
- Testing
- bortezomib
- Volunteers
- 104 people
- Sponsor
- Janssen Korea, Ltd., Korea
Multiple Myeloma
A Study of Bortezomib as Consolidation Therapy in Patients With Multiple Myeloma
The purpose of this study is determination of the event-free survival with and without Bortezomib consolidation therapy from the day of the first chemotherapeutic, myeloma-specific therapy measure, up to the occurrence of…
- Trial name
- NCT00416273
- Testing
- Bortezomib, No intervention
- Where
- 38 sites in Germany
- Volunteers
- 217 people
- Sponsor
- Janssen-Cilag G.m.b.H
Multiple Myeloma
Examination of Trends in Multiple Myeloma Trial Patient Experiences
Historically, participation in clinical trials has been highly skewed towards specific demographic groups. However, research identifying which trial attributes impact participation, in either positive or negative ways, is…
- Trial name
- NCT05860179
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Benign or Malignant Disease Indicated for Colectomy
Harmonic ACE®+7 Shears in Laparoscopic Colectomy
This is a prospective, non-randomized, single arm, multicenter, observational study to assess the initial clinical experience with the Harmonic ACE®+7 Shears by evaluating vessel sealing during laparoscopic colectomy.
- Trial name
- NCT02248246
- Testing
- Harmonic ACE®+7 Shears
- Where
- 4 sites in United States, Belgium and 1 more
- Volunteers
- 40 people
- Sponsor
- Ethicon Endo-Surgery
Multiple Myeloma
Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM
This is an open-label Phase 1/2a study which will enroll patients that have relapsed or relapsed-refractory multiple myeloma to combination regimens of melflufen with currently approved agents.
- Trial name
- ANCHOR (NCT03481556)
- Testing
- Melphalan flufenamide (Melflufen), Dexamethasone, Bortezomib
- Where
- 16 sites in United States, Czechia and 2 more
- Volunteers
- 56 people
- Sponsor
- Oncopeptides AB
Multiple Myeloma
Study Comparing STR (Skeletal Targeted Radiotherapy) Plus Melphalan to Melphalan Alone, With Stem Cell Transplant in Multiple Myeloma
STR (Skeletal Targeted Radiotherapy, 166Ho-DOTMP) is an investigational radiopharmaceutical that delivers radiation directly to cancer cells in the bone and bone marrow.
- Trial name
- NCT00083564
- Testing
- STR(TM) (Skeletal Targeted Radiotherapy, Holmium-166-DOTMP)
- Where
- 21 sites in United States, Canada
- Volunteers
- 240 people
- Sponsor
- Poniard Pharmaceuticals
Multiple Myeloma
Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)
The purpose of this study is to assess the clinical effectiveness of all approved multiple myeloma (MM) therapies in the newly-diagnosed (NDMM) and the relapsed/refractory MM (RRMM) settings in real-world clinical practice.
- Trial name
- NCT01838512
- Where
- 130 sites in United States, Canada and 4 more
- Volunteers
- 2,555 people
- Sponsor
- Bristol-Myers Squibb
Relapsed and Refractory Multiple Myeloma
Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma
The purpose of this study is to evaluate the safety, tolerability and overall response rate of carfilzomib in combination with dexamethasone for the treatment of multiple myeloma in China.
- Trial name
- NCT03029234
- Testing
- Dexamethasone, Carfilzomib
- Where
- 17 sites in China
- Volunteers
- 126 people
- Sponsor
- Amgen
Multiple Myeloma
PRospective Multiple Myeloma Impact Study
This will be a prospective, case-only, study to measure the impact of MMprofiler on treatment intention decisions in Multiple Myeloma patients.
- Trial name
- PROMMIS (NCT02911571)
- Testing
- MMprofiler SKY92 gene signature
- Where
- 9 sites in United States
- Volunteers
- 250 people
- Sponsor
- SkylineDx
Relapsed or Refractory Multiple Myeloma
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
The purpose of the study is to evaluate safety and tolerability of the combination of cevostamab plus elranatamab and also determine the recommended Phase II regimen (RP2R) for the study treatment.
- Trial name
- NCT05927571
- Testing
- Cevostamab, Elranatamab, Tocilizumab
- Where
- 14 sites in Australia, Israel and 1 more
- Volunteers
- 120 people
- Sponsor
- Genentech, Inc.
Multiple Myeloma
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
To evaluate the best overall response rate, safety and tolerability of carfilzomib in patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT00530816
- Testing
- carfilzomib
- Where
- 30 sites in United States, Canada
- Volunteers
- 164 people
- Sponsor
- Amgen
Heart Failure, High Blood Pressure
BVA-200 vs BVA-100 Validation Study
The proposed study is a prospective, observational, investigator and patient blinded study comparing the results of blood volume measurement using the FDA-cleared Daxor BVA-100 device to the Daxor BVA-200 device.
- Conditions
- Heart Failure, High Blood Pressure, High Cholesterol, Anemia
- Trial name
- NCT06227819
- Testing
- BVA-200
- Where
- United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Daxor Corporation
Hemophilia A
Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec, With Prophylactic Steroids in Hemophilia A
This Phase III clinical study will evaluate the safety and effectiveness of valoctocogene roxaparvovec in combination with prophylactic corticosteroids in patients with severe hemophilia A.
- Trial name
- GENEr8-3 (NCT04323098)
- Testing
- valoctocogene roxaparvovec
- Where
- 12 sites in United States, Australia and 2 more
- Volunteers
- 22 people
- Sponsor
- BioMarin Pharmaceutical
Coronary Heart Disease, Coagulation Disorder
Anfibatide Phase 1 Clinical Trial in Healthy Volunteers
In this 94 healthy subjects Phase I clinical trial, we assess the clinical profile of Anfibatide, a specific glycoprotein Ib antagonist.
- Trial name
- NCT01588132
- Testing
- Anfibatide
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Lee's Pharmaceutical Limited
Multiple Myeloma
A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of Use
To understand the safety and efficacy of Revlimid® 5 mg Capsules (hereinafter referred to as Revlimid) in patients with "relapsed or refractory multiple myeloma" (hereinafter referred to as "relapsed or refractory MM") who have…
- Trial name
- NCT02922543
- Where
- Japan
- Volunteers
- 361 people
- Sponsor
- Celgene
Hemostasis, General Surgery
A Study Evaluating the Safety and Preliminary Efficacy of sFilm-FS in Controlling Parenchymal Bleeding During Elective Hepatic Surgery
The Study investigates a new product, sFilm-FS, aimed to help controlling body fluid leakage in general surgery procedures, proposing its use as an adjunct to hemostasis and/or sealing.
- Trial name
- NCT04660721
- Testing
- sFilm-FS, TACHOSIL®
- Where
- 4 sites in United States, Austria and 1 more
- Volunteers
- 33 people
- Sponsor
- Sealantium Medical Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.